Abstract

Endothelial cells express neuropilin 1 (NRP1), endoglin (ENG) and vascular endothelial growth factor receptor 2 (VEGFR2), which regulate VEGF-A-mediated vascular development and angiogenesis. However, the link between complex formation among these receptors with VEGF-A-induced signaling and biology is yet unclear. Here, we quantify surface receptor interactions by IgG-mediated immobilization of one receptor, and fluorescence recovery after photobleaching (FRAP) measurements of the mobility of another coexpressed receptor. We observe stable ENG/NRP1, ENG/VEGFR2, and NRP1/VEGFR2 complexes, which are enhanced by VEGF-A. ENG augments NRP1/VEGFR2 interactions, suggesting formation of tripartite complexes bridged by ENG. Effects on signaling are measured in murine embryonic endothelial cells expressing (MEEC+/+) or lacking (MEEC-/-) ENG, along with NRP1 and/or ENG overexpression or knockdown. We find that optimal VEGF-A-mediated phosphorylation of VEGFR2 and Erk1/2 requires ENG and NRP1. ENG or NRP1 increase VEGF-A-induced sprouting, becoming optimal in cells expressing all three receptors, and both processes are inhibited by a MEK1/2 inhibitor. We propose a model where the maximal potency of VEGF-A involves a tripartite complex where ENG bridges VEGFR2 and NRP1, providing an attractive therapeutic target for modulation of VEGF-A signaling and biological responses.

A mechanistic study provides insight into complex formation between neuropilin-1, endoglin and VEGFR2 as well as the functional consequences of such associations in VEGF-A induced angiogenesis.

Details

Title
NRP1 interacts with endoglin and VEGFR2 to modulate VEGF signaling and endothelial cell sprouting
Author
Sharma, Swati 1 ; Ehrlich, Marcelo 2   VIAFID ORCID Logo  ; Zhang, Manqi 3 ; Blobe, Gerard C. 4 ; Henis, Yoav I. 1   VIAFID ORCID Logo 

 George S. Wise Faculty of Life Sciences, Tel Aviv University, Department of Neurobiology, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 George S. Wise Faculty of Life Sciences, Tel Aviv University, Shmunis School of Biomedicine and Cancer Research, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Duke University Medical Center, Department of Medicine, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216) 
 Duke University Medical Center, Department of Medicine, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216); Duke University Medical Center, Department of Pharmacology and Cancer Biology, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216) 
Pages
112
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2916532507
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.